The Protective Role of Adiponectin for Lipoproteins in End-Stage Renal Disease Patients: Relationship with Diabetes and Body Mass Index

Autor: Sara Nunes, Sofia D. Viana, Vasco Miranda, Susana Rocha, José Madureira, Alice Santos-Silva, Elsa Bronze-da-Rocha, Flávio Reis, Susana Coimbra, João C. Fernandes, Luís Belo, Maria do Sameiro-Faria, Cristina Catarino, José Gerardo Oliveira, Petronila Rocha-Pereira, Maria João Valente
Rok vydání: 2019
Předmět:
Male
0301 basic medicine
Aging
Very low-density lipoprotein
030204 cardiovascular system & hematology
Biochemistry
Body Mass Index
chemistry.chemical_compound
0302 clinical medicine
Índice de massa corporal
biology
medicine.diagnostic_test
lcsh:Cytology
General Medicine
Middle Aged
Humanos
C-Reactive Protein
Female
lipids (amino acids
peptides
and proteins)
Adiponectin
Adiponectina
Research Article
medicine.medical_specialty
Article Subject
Lipoproteins
Adipokine
Lipoproteínas
Protective Agents
behavioral disciplines and activities
End stage renal disease
03 medical and health sciences
Falência renal crónica
Internal medicine
Diabetes Mellitus
medicine
Humans
lcsh:QH573-671
Aryldialkylphosphatase
business.industry
Cholesterol
Paraoxonase
nutritional and metabolic diseases
Cell Biology
030104 developmental biology
Endocrinology
chemistry
biology.protein
Kidney Failure
Chronic
Lipid profile
business
Lipoprotein
Zdroj: Oxidative Medicine and Cellular Longevity
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Agência para a Sociedade do Conhecimento (UMIC)-FCT-Sociedade da Informação
instacron:RCAAP
Oxidative Medicine and Cellular Longevity, Vol 2019 (2019)
ISSN: 1942-0994
1942-0900
DOI: 10.1155/2019/3021785
Popis: Cardiovascular disease (CVD) events are the main causes of death in end-stage renal disease (ESRD) patients on dialysis. The number and severity of CVD events remain inappropriate and difficult to explain by considering only the classic CVD risk factors. Our aim was to clarify the changes and the relationship of lipoprotein subfractions with other CVD risk factors, namely, body mass index (BMI) and adipokines, inflammation and low-density lipoprotein (LDL) oxidation, and the burden of the most prevalent comorbidities, diabetes mellitus (DM) and hypertension (HT). We studied 194 ESRD patients on dialysis and 22 controls; lipid profile, including lipoprotein subpopulations and oxidized LDL (oxLDL), C-reactive protein (CRP), adiponectin, leptin, and paraoxonase 1 activity were evaluated. Compared to controls, patients presented significantly lower levels of cholesterol, high-density lipoprotein cholesterol (HDLc), LDLc, oxLDL, and intermediate and small HDL and higher triglycerides, CRP, adiponectin, large HDL, very-low-density lipoprotein (VLDL), and intermediate-density lipoprotein- (IDL) B. Adiponectin levels correlated positively with large HDL and negatively with intermediate and small HDL, oxLDL/LDLc, and BMI; patients with DM (n=17) and with DM+HT (n=70), as compared to patients without DM or HT (n=69) or only with HT (n=38), presented significantly higher oxLDL, oxLDL/LDLc, and leptin and lower adiponectin. Obese patients (n=45), as compared to normoponderal patients (n=81), showed lower HDLc, adiponectin, and large HDL and significantly higher leptin, VLDL, and intermediate and small HDL. In ESRD, the higher adiponectin seems to favor atheroprotective HDL modifications and protect LDL particles from oxidative atherogenic changes. However, in diabetic and obese patients, adiponectin presents the lowest values, oxLDL/LDLc present the highest ones, and the HDL profile is the more atherogenic. Our data suggest that the coexistence of DM and adiposity in ESRD patients on dialysis contributes to a higher CVD risk, as showed by their lipid and adipokine profiles.
Databáze: OpenAIRE
Externí odkaz: